12.12.2022 - Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large B-cell lymphoma (DLBCL)1Patients receiving . Seite 1
Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis) with Hemlibra from birth in previously untreated or minimally treated infants with severe haemophilia
Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse